-
FDA OKs Genzyme plant in Massachusetts
CAMBRIDGE, Mass. — The Food and Drug Administration has approved a new manufacturing plant that will be operated by drug maker Genzyme.
Genzyme said the plant, located in Framingham, Mass., will help the company continue the production of Fabrazyme (agalsidase beta), a Fabry disease treatment, so that patients can be return to the full dosing levels (1 mg/kg).
-
Oxecta now commercially available
PALATINE, Ill. — A pain medication that utilizes Acura Pharmaceuticals' Aversion technology now is commercially available.
Acura said it was informed by Pfizer that Oxecta has hit the market in 5-mg and 7.5-mg strengths, which will be sold in 100-count bottles. Oxecta is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.